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2 LIST OF ABBREVIATIONS 
 
AMA-1  apical membrane antigen 1 
ca.   circa 
ClpQ   threonine peptidase encoded by hslV 
cssurrna  C-type small subunit rRNA 
DC   dendritic cell 
dpi   days post infection 
dssurrna  D-type small subunit rRNA 
ECM   experimental cerebral malaria 
e.g.   example given 
fig.   figure 
GPI   glycosylphosphatidylinositol 
hdhfr   human dihydrofolate reductase 
hslV   heat shock locus V 
hslV-KO  hslV knockout 
i.e.   in explanation 
i.p.   intraperitoneally 
iRBCs   infected red blood cells 
IU   international units 
i.v.   intravenously 
LB medium/agar lysogeny broth medium/agar 
MyD88  myeloid differentiation primary response gene 88 
MyD88-KO  MyD88 knockout 
N/A   not applicable 
PAMP   pathogen associated molecular pattern 
pbeef1aa 5´UTR of P. berghei elongation factor 1 alpha (not stage-specific 
promoter sequence) 
PfEMP1  Plasmodium falciparum erythrocyte membrane protein 1 
PRR   pattern recognition receptor 
RBC   red blood cell 
RT   room temperature 
s.c.   subcutaneously 
SOB medium super optimal broth 
SOC medium SOB with added glucose 
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spp.   species 
tgdhfr   toxoplasma gondii dihydrofolate reductase 
TLR   Toll-like receptor 
vs.   versus 
WT   wild type 
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3 INTRODUCTION AND LITERATURE SURVEY 
3.1 General introduction to malaria 
3.1.1 Malaria host range and parasite species 
Malaria, caused by apicomplexan parasites of the genus Plasmodium, is a vector-
borne infectious disease, which is transmitted by mosquitoes of the genus 
Anopheles. Many Plasmodium spp. are important pathogens for humans as well as 
for animals. In humans, malaria is caused by five different Plasmodium spp., namely 
P. falciparum, P. vivax, P. ovale, P. malariae, and by the simian malaria parasite P. 
knowlesi. Besides humans, various birds, rodents, reptiles, and primates can be 
infected by a total of 199 Plasmodium spp. (Martinsen et al. 2008). Usually 
Plasmodium spp. have a narrow host range, i.e. each species has a single genus or 
even species of host that it can infect (Boothroyd 2009). Although this hampers 
deductions on human disease from animal model derived data, such models can still 
be valuable tools for the investigation of processes, which are conserved between 
parasite species. The potential of the simian parasite P. knowlesi to infect humans 
makes malaria a zoonosis [for a review see Baird (2009)]. 
 
3.1.2 The public health impact of malaria 
In 2008, a total of about 243 million clinical malaria cases were reported and nearly 
863,000 patients died, mostly children under 5 years (World Malaria Report 2009). 
The disease is widespread within tropical and subtropical regions, especially in sub-
saharan Africa, South and Central America, and Southeastern Asia. Malaria poses 
therefore one of the most important public health problems worldwide. Nevertheless, 
recent campaigns aim to control, eradicate and eliminate malaria, an option that 
seems possible in view of intensified funding, new interventional tools, improved 
global cooperation and a worldwide declining disease prevalence (Global Malaria 
Action Plan 2008). However, previous experiences have shown that resistance 
against antimalarial drugs as well as against insecticides to control its mosquito 
vector may evolve rapidly and unexpectedly, making long-term forecasts regarding 
development of disease prevalence difficult and ongoing efforts to develop new tools 
against the malaria parasite necessary (Kilama and Ntoumi 2009). Up to date, there 
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is no malaria vaccine available, although clinical trials for some vaccine candidates 
are ongoing. Plasmodia have been proven to be capable of resistance development 
against all classes of antimalarials used so far. Even though the risk of resistance 
development can be lowered by using combinations of different drugs, as e.g. in 
Artemisinin-based combination therapy (ACT), there remains a persistent threat of 
resistance, which means that new molecules with novel mechanisms of action are 
continually required (Wells et al. 2009). Further complications may arise through 
climatic changes, which could even put previously disease-free, temperate areas at 
risk for malaria spreading. Taken together, malaria remains a serious global health 
problem, which requires continuous efforts for its control. 
 
3.1.3 Life cycle of the malaria parasite plasmodium 
(see even Fig. 1) 
Humans (and other vertebrates) are infected with plasmodia by a bite of mosquitoes 
of the genus Anopheles. Following infection, injected sporozoites first migrate to the 
liver, where they undergo nuclear division, thereby developing into liver schizonts. 
Eventually, these schizonts release the contained merozoites into the bloodstream. 
Within the blood stream, parasites immediately invade erythrocytes and develop 
within these host cells into trophozoites and later into multinucleated, merozoite-
containing schizonts. Merozoites of blood schizonts are freed through schizont 
egress and invade subsequently new red blood cells. The development of the blood 
stages is responsible for the clinical signs of malaria, a fact that makes them 
especially important for researchers and healthcare practitioners alike. 
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Fig. 1 
 
3.2 Reverse genetics in malaria research 
3.2.1 Transfection techniques for plasmodia 
The application of reverse genetics strategies to malaria research has facilitated the 
understanding of many plasmodial gene functions. Genetic modification allows to 
elucidate gene functions by phenotyping of genetically modified, e.g. knockout 
parasites. Unfortunately, this approach is hampered by the paucity of information 
regarding gene regulation in Plasmodium spp.. Although precise regulation of protein 
expression seems to be mandatory in the light of different parasitic stages, a 
changing environment within the host organisms or virulence-associated processes 
such as cytoadherence or erythrocyte invasion, the transcriptional regulations of such 
processes remain poorly understood. Only very few transcription factors have been 
identified so far, and there is evidence that post-transcriptional regulation may play a 
significant role in plasmodia (Coleman and Duraisingh 2008, Deitsch et al. 2007). 
Nevertheless, transfection experiments have still elucidated a variety of gene 
 9
functions in Plasmodium spp.. Transfection possibilities for malaria parasites are 
reviewed by de Koning-Ward et al. (2000b) and by Balu and Adams (2007) and are 
briefly summarized below. 
Today it is possible to stably transfect the human parasite P. falciparum,  the simian 
parasites P. knowlesi and P. cynomolgi as well as the rodent parasites P. berghei, P. 
yoelii, and P. chabaudi. Although it seems favourable to undertake investigations in 
P. falciparum, the transfection of this parasite species is hampered by extremely low 
transfection efficiencies and difficulties to isolate transfectants with integrated 
constructs. Although in vivo experiments are theoretically possible, analysis of 
transfected parasites is restricted to in vitro investigation. These drawbacks apply to 
a lesser extend even for the simian parasites. For those reasons many reverse 
genetic studies in malaria have been done using rodent malaria parasites. Especially 
the murine malaria parasite P. berghei, which is described in more detail in the 
following section, has proven to be very suitable for genetic manipulations.  
 
3.2.2 The Plasmodium berghei model organism in reverse genetics 
P. berghei is the most frequently employed malaria model organism in reverse 
genetics. According to a protocol developed by Janse et al. (2006), transfection 
efficiencies reach one in 10−2 to 10−3, compared to one in 10-6 in P. falciparum. The 
model allows transfection of linear instead of circular DNA, which facilitates genomic 
integration via single or double-crossover. A multitude of established vectors with 
different reporter genes and promoter types is available. Better parasite growth rates 
allow the isolation of transfected parasite clones with stably integrated constructs 
within a few weeks, compared to several months in P. falciparum, which facilitates 
medium throughput experiments. Furthermore, the effects of genetic manipulations 
can be assessed in vivo. Disadvantages are the unclear relevance from 
investigations in the murine host for human disease, a paucity of selectable markers, 
the limited number of parasites that can be recovered per experiment restricting their 
biochemical characterization, and the impracticality of long-term in vitro culture. 
Nevertheless, the P. berghei model still may reveal valuable insights into host-
pathogen interactions especially regarding conserved biochemical pathways. 
P. berghei transfection is achieved by electroporation of schizonts, using the 
AmaxaTM Nucleofector device (Janse et al. 2006). Transfected parasites are injected 
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i.v. into a mouse and subsequently selected from the total parasite population by 
antibiotic treatment of this mouse. This selection is facilitated by a selectable marker 
sequence that is part of the transfected DNA and confers resistance to the selective 
agent, usually pyrimethamine or WR99210 (see even fig. 3 in section 5.3.6). 
Subsequent phenotyping of cloned, transfected parasites facilitates conclusions 
regarding the function of modified genes. In this thesis, characterization of the 
parasite-specific protease hslV was facilitated by phenotyping of hslV knockout (hslV-
KO) and knockout rescue parasites. 
 
3.3 The protease ClpQ encoded by the gene hslV 
3.3.1 The function of ClpQ in protein degradation  
All living cells rely on intracellular proteolysis to remove, tagged, unneeded or 
damaged proteins, and to maintain protein homeostasis. For Plasmodium spp. 
regulation of protein turnover is especially important due to high replication rates of 
the blood-stage parasites, stress on proteins caused by increased temperature (fever 
of the host), the large size of plasmodial proteins, the high frequency of low 
complexity regions within the plasmodial genome (Kreidenweiss et al. 2008), and a 
high degree of posttranscriptional control of protein levels (Deitsch et al. 2007). 
During evolution, different organisms have developed distinct proteolytic machineries 
to control protein turnover. In eukaryotes, archaea, and some bacteria proteolysis is 
accomplished by the 20S proteasome, a large ATP-dependent, multisubunit 
proteolytic complex, whereas the majority of bacteria possess several different 
proteolytic enzymes, amongst others a proteasome-like heat shock protein encoded 
by heat shock locus V, hslV (Groll et al. 2005). Despite this general taxonomic 
classification, it has been shown that the two degradation mechanisms appear not 
mutually exclusive, but are both present in some protozoa, e.g. in Plasmodium spp. 
(Gille et al. 2003). Mordmüller et al. (2006) discovered that the plasmodial 
proteasome is catalytically active and expressed throughout the life cycle, whereas 
hslV is expressed exclusively during late parasitic stages. The hslV-coding sequence 
is highly conserved between different Plasmodium spp., which indicates purifying 
selection on this gene suggesting an essential function of hslV. 
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3.3.2 Molecular structure of ClpQ 
The gene hslV codes for the threonine peptidase ClpQ, which shares 20% similarity 
and a conserved fold with the β subunits of the proteasome (Bochtler et al. 2000). 
The hslV gene product consists of a 37aa (18kDa) long pro sequence, which targets 
the molecule into mitochondria (Tschan et al. 2010), followed by the 170aa (23kDa) 
mature protease, which is activated by removal of the targeting signal. The mature 
protease forms a dodecameric barrel-like structure. Analogous to the 20S 
proteasome its openings possess polar caps, here represented by the ATPase HslU, 
a member of the Hsp100 (Clp) family of ATPases, which actively channels proteins 
destined for degradation into the interior of the hslV complex (Bochtler et al. 2000). 
Due to its highly conserved sequence among Apicomplexan spp., hslV appears to 
play a fundamental role in plasmodial cell metabolism. Its absence in the mammalian 
host makes it an attractive target for future interventional approaches especially since 
potent and selective inhibitors can be designed against this molecule (Elofsson et al. 
1999, Powers et al. 2002). 
This thesis investigates its function in a murine malaria model, by generating hslV-
deficient P. berghei parasites and subsequent characterization of these parasites. 
 
3.4 Host parasite interactions during plasmodium infections 
3.4.1 Introduction 
Symptoms caused by malaria include intermittent fever, shivering, arthralgia, anemia, 
metabolic acidosis, organ dysfunction and, in cases of cerebral malaria, convulsions 
and coma (Stich 2009). The severity of the clinical picture can vary considerably and 
is determined by an interplay of many host- and parasite-associated factors, such as 
the immune status of the host, parasitemia, and virulence of the infecting parasite 
strain. 
Symptoms are mainly caused by a parasite-induced proinflammatory immune 
response (Franklin et al. 2009). On the other hand, malaria leads even to a partial 
immunosuppression of the host (Urban and Todryk 2006). The reasons for this 
regulation of both innate and acquired immune responses remain unclear. Despite 
the fact that parasites can persist within the host for extended periods of time, 
immunity against plasmodia develops only slowly, and long-term immunity requires 
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repeated pathogen exposure (Langhorne et al. 2008). Plasmodia are highly adapted 
to the environment within their host. Their complex life cycle, which comprises 
multiple, immunologically distinct forms, enables them to evade or even suppress 
host immune responses, despite the induction of both the innate and the adaptive 
immune system (Coban et al. 2007). These complex interactions between parasite 
and immune system of the host make the development of new therapeutic or 
prophylactic tools like antimalarial drugs or vaccines especially challenging. 
Therefore, a better understanding of host-parasite-interactions seems mandatory to 
find new targets for pharmacological or prophylactic intervention. 
 
3.4.2 The eukaryotic immune system 
The function of the eukaryotic immune system is to protect the organism from 
disease by recognizing and eliminating pathogens or tumour cells. It is divided into 
the innate (unspecific) and the adaptive (specific) immune system. In view of vaccine 
development efforts, malaria research was until recently mainly focused on adaptive 
immunity, but there is increasing evidence that innate immune mechanisms are of 
critical importance for malaria protection and that a comprehensive understanding of 
those mechanisms is of importance for the development of new anti-malarial agents 
(Stevenson and Riley 2004). 
The innate immune system comprises cells and mechanisms that protect the 
organism in a non-specific manner. It provides an immediate first line defence against 
invading pathogens and is the main activator of acquired immune responses. 
Important components of the innate immune system are phagocytic cells 
(macrophages, monocytes and neutrophils), cells that release inflammatory 
mediators (basophils, mast cells and eosinophils) and natural killer cells as well as 
soluble mediators such as acute phase proteins, cytokines and complement 
components (Delves and Roitt 2000). 
3.4.3 PAMPs and pattern recognition receptors 
The innate immune system senses invading pathogens through so-called pattern 
recognition receptors (PRRs). PRRs are activated through pathogen-associated 
molecular patterns (PAMPs), i.e. small molecular motifs conserved within distinct 
classes of pathogens, which are not expressed in the host organism itself (Medzhitov 
2007). PRRs are divided into different groups, most importantly the Toll-like receptors 
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(TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs) and C-Type lectin 
receptors (Ishii et al. 2008, Rasmussen et al. 2009). All TLRs except TLR3 depend 
on a common adapter molecule named myeloid differentiation primary response 
gene 88 (MyD88) to activate downstream signaling cascades. Upon TLR ligand 
binding, MyD88 mediates the activation of nuclear factor-kappaB (NF-κB), interferon 
regulatory factors (IRFs) and mitogen-activated protein kinases (MAPKs), all 
members of pathways that stimulate inflammatory responses, such as induction of 
pro-inflammatory cytokines and interferon-inducible genes (Rasmussen et al. 2009, 
Waters et al. 1997). Due to this central role of MyD88 for TLR-signaling, TLR 
involvement in pathogenic processes can be assessed by comparison of this process 
in a normal compared to a MyD88-deficient host, i.e. intact and MyD88 knockout 
(MyD88-KO) mice. 
 
3.4.4 The role of PRRs and PAMPs during Plasmodium infections 
It still remains unclear which plasmodia-specific PAMPs lead to TLR activation during 
plasmodium infections. Currently the two main candidates for plasmodial PAMPs are 
the plasmodial pigment hemozoin and the glycosylphosphatidylinositol (GPI) anchor. 
GPIs are eukaryotic glycan molecules that anchor surface proteins into plasma 
membranes. Plasmodial GPIs are structurally distinct from vertebrate GPIs and 
considered as plasmodial PAMPs, which evoke a proinflammatory immune response 
by signaling via TLR2 and 9 (Coban et al. 2007a, Gowda 2007, Arrighi and Faye 
2009). 
While GPI is believed to evoke a proinflammatory response, the role of hemozoin in 
host-parasite interactions remains unclear. Urban and Todryk (2006) claim that 
hemozoin modulates dendritic cell (DC) function of the host, leading to an impaired 
induction of adaptive immune responses, whereas Griffith et al. (2009) found a 
proinflammatory immune response in stimulation studies with synthetic hemozoin. 
Coban et al. (2005) report that hemozoin is modulating the innate immune response 
by binding to TLR9. A hemozoin-mediated TLR9 activation was also proposed by 
Parroche et al. (2007) who propose that the activation is not triggered by hemozoin 
itself, but by hemozoin-presented plasmodial DNA, a thesis that is contradictory to 
the results of Griffith et al. (2009). Despite inconsistencies of results, these and other 
studies nevertheless suggested hemozoin as a candidate for a plasmodial PAMP. 
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To date Toll-like receptors (TLRs) seem to be the most important PRR group during 
the innate immune response. Another PRR that is suspected to be involved in 
parasite-induced immunosuppression is the class B scavenger receptor CD36. 
Whether CD36 contributes to innate host defence or rather to pathophysiology 
remains controversial (Areschoug and Gordon 2009). CD36 is a receptor for 
Plasmodium-infected red blood cells (iRBCs). In P. falciparum the main ligand for 
CD36 is Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). PfEMP1 
is thought to mediate sequestration of iRBCs, which in turn may lead to increased 
disease severity and enhanced parasite survival [reviewed by Serghides et al. 
(2003). In P. berghei, PfEMP1 is not present, but Franke-Fayard et al. (2005) showed 
that CD36-mediated sequestration of iRBCs even occurs in the absence of PfEMP1. 
Furthermore, CD36 acts as a co-receptor for the TLR2/TLR6 complex (Akashi-
Takamura and Miyake 2008), which means that signaling pathways involving CD36 
could also be impaired in MyD88-KO mice. 
Taken together these facts about the innate immune response suggest that TLRs 
play a major role in innate immune responses to malaria parasites. For this reason, 
their involvement in mediation of the phenotypic differences between WT- (wild type) 
and hslV-KO parasites was investigated in this thesis by infection of MyD88-KO mice.  
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4 HYPOTHESIS AND DISSERTATION OBJECTIVE 
 
This thesis aims to characterize the function of the threonine peptidase hslV in 
Plasmodium spp. by means of reverse genetics. Since the highly conserved 
sequence of hslV suggests an essential role of the protease, investigations aimed to 
clarify, whether hslV is essential for the malaria parasite, and to investigate its 
possible function in the rodent model P. berghei. To achieve this goal hslV-KO-
parasites were generated and characterized with respect to physiological and 
immunological parameters. 
To prove that the hslV-knockout itself led to the observed phenotypic changes in the 
knockout-parasites, rescue-parasites, i.e. hslV-KO-parasites, cotransfected with a 
hslV-expression-cassette in a different genomic locus were generated. To control for 
effects caused by alteration of the cotransfected locus (c- or d-ssurrna), a mock-
transfected parasite line, containing a transfection construct, identical to the rescue 
construct, but lacking the hslV-coding-sequence was generated and phenotypes of 
both mock and rescue parasites compared to the hslV-KO-parasites. 
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5 MATERIALS AND METHODS 
A detailed list of reagents can be found at the end of the chapter. 
 
5.1 General methods for molecular cloning 
5.1.1 Plasmid transformation 
For amplification 50ng plasmid DNA were mixed with 50µl competent bacteria (i.e. 
XL-10 Gold (Stratagene) or TOP-10 (Invitrogen) chemically competent Escherichia 
coli cells), incubated on ice for 10min and subsequently heat-shocked at 42°C for 
45s. Immediately thereafter, 250µl SOC medium was added; the culture was shaken 
at 37°C for 60min and then streaked out on a LB agar plate containing the 
appropriate antibiotic for selection of the transformed plasmid (ampicillin or 
kanamycin). 
 
5.1.2 Plasmid-DNA isolation 
Depending on the required amount of DNA, plasmid DNA was isolated using either 
the “peqGOLD HP Plasmid Miniprep Kit I” (Peqlab) or the “Qiagen® Plasmid Maxi Kit” 
(Qiagen) according to the manufacturer’s instructions. 
Basic principles of the used kits: 
In both procedures plasmid DNA is selectively lysed using a modified alkaline lysis 
procedure and extracted by adsorption onto a silica-gel spin column followed by 
washing steps. For small scale preparations (Mini-Preps) DNA was subsequently 
eluated under low salt conditions. For large scale preparations (Maxi-Preps) DNA 
was eluted using high-salt buffer conditons and finally concentrated and desalted by 
isopropanol precipitation. 
 
5.1.3 Measurement of DNA content of samples 
To determine the DNA content of plasmid or genomic DNA prior to ligation, 
transfection, PCR, or sequencing, DNA concentration was quantified by measuring 
the samples´ absorbance at 260 nm using a NanoDrop® ND-1000 spectrophotometer 
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(NanoDrop Technologies, Inc., Wilmington USA) according to the manufacturer’s 
instructions. 
 
5.1.4 DNA ligation 
Prior to ligation, restricted DNA fragments were separated by agarose gel 
electrophoresis, cut out of the gel and purified using the “NucleoSpin® Extract II Kit” 
(Macherey-Nagel) according to the manufacturer’s instructions. 
For ligations at two identical restriction sites vector DNA was dephosphorylated using 
“rAPid Alkaline Phosphatase®” (Roche). 
Maximal possible amounts of insert and vector DNA were used in the ligation 
reaction as calculated using the following formula, which determines the amounts of 
DNA for a 10:1 insert: vector ratio: 
INSERT MASS [ng] = INSERT LENGTH [bp] / VECTOR LENGTH [bp] x VECTOR MASS [ng] X 10 
 
DNA was ligated overnight at 16°C using T4 DNA ligase (Fermentas). Subsequently, 
ligation reactions were directly transformed into competent bacteria for amplification. 
Transformants containing the desired insert were identified by colony PCR, restriction 
enzyme analysis, and sequencing. For colony PCR a standard PCR master mix, as 
described in section 5.4.3, was used. Primers and thermocycler settings for the 
different products are given in table 1 (section 5.2.4) and in section 5.4.4 
respectively. The PCR reactions were inoculated with one bacterial colony serving as 
template. After inoculation, residual colony material was transferred to a defined area 
of a selective agar plate to spare the respective clones for future purposes. Plasmid 
DNA from positive clones was analyzed by restriction enzyme analysis and/or 
sequencing of the insert. 
 
5.1.5 Sequencing 
To confirm their correct sequences, all cloned fragments were sequenced on an ABI 
PRISM® 3100 Genetic Analyzer (Applied Biosystems). 
Sequencing samples were generated using the “BigDye® Terminator v1.1 Cycle 
Sequencing Kit” and the following reaction mix: 
2µl 2.5x Ready Reaction Premix, 4µl 5x BigDye Sequencing Buffer, 3.2 pmol primer, 
200ng template, water up to 20µl 
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Thermocycler: Biometra UNO II 
Settings: (94°C – 10s, 50°C – 5s, 60°C – 4min, 24 cycles), 72°C 7 min 
PCR products were subsequently purified to remove unincorporated dye terminators 
using Centri-Sep™ spin columns (Applied Biosystems) according to the 
manufacturer’s instructions. 
Sequences were analyzed using the BioEdit sequence alignment editor.  
 
5.2 Cloning of transfection vectors 
5.2.1 General vector description 
Generally, selection of transfected parasites is facilitated by the introduction of a 
selectable marker that confers resistance to pyrimethamine, such as the 
dihydrofolate reductase (dhfr) gene from Toxoplasma gondii (tgdhfr) or the human 
dhfr gene (hdhfr). hdhfr confers not only pyrimethamine resistance, but also 
resistance to the antimalarial drug WR99210, which facilitates its use as a second 
selectable marker in tgdhfr-transfected parasites (Janse et al. 2006). 
The initial hslV-KO construct contained the selectable marker hdhfr flanked by ca. 
500bp of pbhslV 5´ and 3´UTR sequences to facilitate integration at the genomic hslV 
locus via double crossover. 
To rescue this knockout, it became necessary to clone a second knockout vector, 
similar to the first one, but containing tgdhfr instead of hdhfr. 
Parasites transfected with this second, tgdhfr-selectable knockout vector allowed the 
introduction of hdhfr as a second selectable marker to select for cotransfected 
parasites, additionally containing the rescue/mock construct with WR99210. 
The rescue vector contained two expression cassettes, one for the selectable marker 
hdhfr and another for pfhslV as well as a ca. 2KB long homologous sequence to 
facilitate integration into the genome of P. berghei at the cssurrna or dssurrna gene 
locus via single crossover. The mock vector was identical to the rescue vector, but 
lacked the pfhslV sequence. 
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5.2.2 Maps of transfection vectors 
 
 
Fig. 2: Transfection vectors. 
Left: first knockout vector, middle: second knockout vector used for rescue cotransfection, right: 
rescue construct [mock vector = identical to rescue vector, but without pfhslV sequence (black 
segment)]. Indicated restriction sites were used to linearize the constructs prior to transfection. 
 
 
5.2.3 Plasmids for cloning of transfection vectors 
The standard P. berghei transfection vectors pl0005, pl0006, pl0010 and pl0031 were 
obtained from the MR4, ATCC®, Manassas, Virginia, USA. All those vectors are 
MR4 deposits of A. Waters, Leiden Malaria Research Group, LUMC, Netherlands 
(website reference: P. berghei - Plasmids for genetic modification). 
 
5.2.4 Cloning procedure 
Homologous pbhslV sequences were amplified from genomic P. berghei DNA and 
pfhslV from plasmid DNA using the primers listed in table 1. PCR fragments were 
subsequently cloned into the pCR®2.1-TOPO® Vector (Invitrogen) and sequenced to 
verify correct amplification (sequencing was performed as described in section 5.1.5). 
Except for the pbhslV 3´UTR, fragments were cloned using primer-specific restriction 
sites. 
For the first, hdhfr-selectable knockout vector, the amplified pbhslV 3´UTR fragment 
was modified by cloning it into the pCR®2.1-TOPO® vector (Invitrogen) and 
subsequent excision with EcoRI. pbhslV 5´UTR and 3´UTR sequences were 
subcloned into pl0005. The resulting plasmid contained a cassette for the expression 
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of the selectable marker hdhfr under the control of the constitutively active pbeef1aa 
promoter flanked by pbhslV 5´UTR and 3´UTR sequences. 
For the second knockout vector with tgdhfr as selectable marker, the 5´UTR of 
pbhslV was amplified from plasmid DNA using the same primer sequences as for the 
first vector, but with KpnI instead of HindIII/PstI restriction sites. The resulting 
fragment was cloned into pl0031. The pbhslV 3´UTR sequence from the construction 
of the first knockout vector was cut out of pCR®2.1-TOPO® using the enzymes NdeI 
and XbaI. The resulting plasmid contained a cassette for the expression of the 
selectable marker tgdhfr under the control of the 5´pbdhfr/TS promoter sequence, 
which is active in old trophozoites, schizonts, and sexual parasite stages. This 
expression cassette is flanked by pbhslV 5´UTR and 3´UTR sequences. Parasites 
transfected with either of those two vectors can be selected by pyrimethamine 
treatment of the infected mice. 
To clone the rescue vector, first total RNA of P. falciparum parasite extracts was 
reverse transcribed with SuperScript® III Reverse Transcriptase (Invitrogen). pfhslV 
was amplified using the primers listed in table 1, cloned into the pCR®2.1-TOPO® 
Vector (Invitrogen) and subcloned into pl0010, using the primer-specific restriction 
sites. The resulting expression cassette contains the schizont-specific promoter ama-
1 and the pfhslV-cDNA sequence of pfhslV. The stage-specific promoter was chosen, 
since plasmodial hslV is expressed during late stages, only. The tgdhfr-selectable 
marker of this plasmid as well as its 5´UTR and 3´UTR sequences were removed by 
EcoRV-HindIII restriction and replaced with the hdhfr sequence from pl0006, 
including its constitutively active promoter pbeef1aa and its 3´UTR 3´pbdhfr/TS. The 
hdhfr-selectable marker facilitates the selection of transfected parasites from a 
pyrimethamine-resistant parasite population using the antimalarial compound 
WR99210. The rescue construct integrates into the c- or dssurrna locus via single 
crossover and can be lost again, if parasites are not kept under constant drug 
pressure. To confirm that phenotypic findings obtained from rescue vector-
transfected parasites are not provoked by this drug treatment, a mock vector identical 
to the rescue vector, but lacking the pfhslV sequence, was cloned using the same 
approach as described above. 
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Name Sequence Restriction site 
(uncapitalized) 
pbhslV 5´UTR-1st KO  for 5´ - TTTa agcttCGTCTTTTGGAATG - 3´ HindIII 
pbhslV 5´UTR-1st KO rev 5´ - TTTctgca gCGCTTAAGTGTAGAAAAC - 3´ PstI 
pbhslV 5´UTR-2nd KO for 5´ - TTTggtaccCGTCTTTTGGAATG – 3´ KpnI 
pbhslV 5´UTR-2nd KO rev 5´ - TTTggtaccCGCTTAAGTGTAGAAAAC - 3´ KpnI 
pbhslV 3´UTR (1st+2nd KO) 
for 
5´ - AAAtctaga CGAATCATAACTTTATATGTG - 3´ XbaI 
pbhslV 3´UTR (1st+2nd KO) 
rev 
5´- TTTaagcttTTCAGGCGTTTATGCATTTG-3´ HindIII 
pfhslV-cDNA for 5' - TTTggatccAACAACTAATTATTCGAAGG - 3' BamHI 
pfhslV-cDNA rev 5' - TTTggtaccCTGACATCCTCTTGATTAG - 3' KpnI 
 
Table 1: Primers for cloned sequences (small letters indicate restriction sites attached to the primers) 
 
 
5.2.5 DNA preparation for transfection 
Double-crossover constructs were linearized by two restriction enzymes at the ends 
of the target sequence as listed below (removal of plasmid backbone). Single 
crossover constructs were linearized at one site within the target sequence as listed 
below. 
 
Construct Integration event Restriction site(s) 
hdhfr-KO Double crossover HindIII+PvuII 
tgdhfr-KO Double crossover XbaI+SapI 
Rescue Single Crossover BspE1 
Mock Single Crossover BspE1 
 
Per transfection 8μg of DNA was digested overnight in portions of 3μg per reaction 
with 30U/reaction of each of the enzymes using appropriate buffer and temperature 
conditions to ensure complete digestion. 
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Subsequently reactions were pooled, and the DNA was precipitated with 0.1 volume 
of 3M NaAc, pH 5.2, and 2.5 volumes of 96% ethanol for 2 hours at room 
temperature or overnight at -20°C and centrifuged (17,000g, 15min, 4°C) to obtain 
the DNA pellet.  
DNA pellets were washed with 200μl of 70% ethanol and resuspended in H2O to a 
concentration of 1 μg/μl. 
 
5.3 Parasitological methods 
5.3.1 Selection of mouse strains and parasites 
All animal work was conducted in accordance with European regulations and 
approved by the local state authorities (Regierungspräsidium Tübingen). For routine 
parasite propagation, transfections and cloning CD1TM outbred mice were used. The 
strain was chosen because of the robust constitution and big size of the animals. 
To assess the genetic influence on immune responses growth assays were 
performed using CD1TM, BALB/c, C57BL/6 and MyD88-KO mice (on the genetic 
background C57BL/6). All animals, except the MyD88-KO mice were purchased from 
Charles River Laboratories (Kisslegg) and kept in a conventional open facility. The 
MyD88-KO mice were a kind gift of Dr. Uwe Klemm (Max-Planck-Institut f. 
Infektionsbiologie, Berlin, Germany). They were kept under sterile conditions in 
individually ventilated cages. 
All experiments were conducted using P. berghei parasites of the ANKA strain (Bafort 
et al. 1968). Parasites were obtained from A. Walliker (Institute of Cell, Animal, and 
Population Biology, University of Edinburgh, United Kingdom). 
 
5.3.2 Mouse infections 
Mice were infected with blood, containing malaria parasites, diluted in parasite 
medium or PBS or with cryopreserved parasites directly after thawing. Parasites were 
administered either intravenously or intraperitoneally. When an exact inoculum size 
was required or only few parasites were present in the inoculum parasites were 
injected i.v. (e.g. for transfection, cloning, or growth assays), for all other purposes 
parasites were administered i.p.. 
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5.3.3 Giemsa staining of blood smears 
To determine the parasitemia, dried thin blood smears were briefly fixed in 100% 
methanol, air-dried and stained for 20min in a 20% Giemsa solution (Giemsa stock 
diluted with Sörensen staining buffer, i.e. 3.7mM KH2PO4, 0.62mM Na2HPO4·2H2O, 
pH adjusted to 7.2 with NaOH). The staining solution was filtered prior to use, (folded 
filter MN615, Macherey-Nagel, Art.-No. 531 024). 
 
5.3.4 Parasite retrieval 
At the desired parasitemia 0.5ml to 1ml blood per mouse was taken by cardiac 
puncture under anesthesia. The blood was immediately mixed with approximately 
100µl heparin stock solution (i.e. 0.5ml Liquemin N 5000 diluted in 25ml parasite 
medium without fetal calf serum = 200IU/ml). Following this, mice were immediately 
sacrificed by cervical dislocation. The infected blood was then used for the desired 
purpose such as schizont culturing, DNA or protein extraction or cryopreservation of 
parasites. 
 
5.3.5 Cryopreservation of parasites 
Freshly taken parasite-infected blood was mixed 1:1 with a glycerol/PBS solution 
(30% glycerol; v/v; containing 5% heparin stock solution of 200IU/ml), the mixture 
was kept on ice for 5-15min and then frozen at -80°C. 
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5.3.6 Parasite transfection 
Parasites were transfected as previously described (Janse et al. 2006) 
The method is described in the following sections (for an overview see fig. 3). 
 
 
Fig. 3: Overview over the P. berghei transfection protocol [modified after (Tomas et al. 1998)]. 
 
5.3.6.1 Schizont culture - Rationale for schizont culturing 
In P. berghei the schizont stage is most suitable for transfections. The schizont 
fraction of a mixed blood-stage parasite population can be increased by culturing the 
parasites in vitro over night. Since parasites have a circadian rhythm and develop 
over night into schizonts that do not rupture under in vitro conditions, overnight 
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cultures yield a parasite population mainly consisting of schizonts, which is most 
suitable for transfection experiments (Janse et al. 2006). 
 
5.3.6.2 Parasite medium 
For short-time in vivo culturing of P. berghei parasites prior to transfection the 
following medium was used [modified after (Waters et al. 1997)]: 
Premix: 
500ml RPMI-1640 Medium with NaHCO3 
12,5ml HEPES solution, 1M 
500µl liquid Gentamicin (50mg/ml) 
5ml L-Glutamine solution, 200mM (stored in aliquots at -21ºC) 
The premix was stored at 4°C. Immediately prior to use, it was warmed to 37ºC and 
“Fetal Bovine Serum GOLD" was added to a final concentration of 25% (v/v). 
Prior to its first use the fetal bovine serum was inactivated for 30min at 56°C and 
subsequently stored in 10ml aliquots. 
 
5.3.6.3 Culturing technique 
To set up the culture, 0.6-1.0ml infected blood was collected from a donor mouse 
with a parasitemia of 1-3%. Blood was collected between 10am and 4pm. 
Upon collection, the blood was mixed with an equal amount of complete culture 
medium containing 5% heparin stock-solution (200IU/ml). Cells were then pelleted by 
centrifugation (8min, 200g), the supernatant was discarded, and the cells 
resuspended in complete culture medium in a 250ml bottle (“PS-Vorratsflasche”, 
Neolab). For 1 ml blood, 30ml complete culture medium were used. The bottle was 
incubated for 15min with the lid loosely closed in an incubator with low oxygen 
tension (37°C, 5% CO2, 5% O2, 90% N2). For overnight culturing, flasks were firmly 
closed and put at 37°C on a rotor to keep cells in suspension. 
 
5.3.6.4 Histodenz® stock solution for gradient centrifugation medium 
138g Histodenz® powder was dissolved in 500ml buffered medium, autoclaved, and 
stored at 4ºC (Buffered medium: 5mmol/l Tris/HCl / pH 7.5, 3mmol/l KCl, 0.3mmol/l 
Ca-Na2EDTA). For the working solution 55% (v/v) Histodenz® stock solution was 
mixed with 45% sterile-filtered PBS. 
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5.3.6.5 Centrifugation Procedure 
The purification procedure was started between 7am and 9am. The culture 
suspension containing the schizonts was transferred to 50ml falcon tubes, and 10ml 
of Histodenz® working solution per tube was added to the culture medium resulting in 
a sharp contrasting line between the two suspensions. The tubes were then 
centrifuged for 20-30 min at 200g at room temperature in a swing-out rotor. Using a 
transfer pipette the brown parasite layer at the interface between the two 
suspensions was collected into a 10ml tube and approx. 4ml culture medium, 
obtained from the top of the gradient, was added. Parasites were now pelleted by 
centrifugation (200g, 8min, normal break setting). After this centrifugation, the 
supernatant was discarded and the schizont pellet resuspended in 1ml of culture 
medium per transfection. A schizont culture containing 1ml blood was used for up to 
four transfections. 
 
5.3.6.6 Nucleofector solutions 
Nucleofector solutions were obtained from Amaxa GmbH (Cologne, Germany). For 
the transfection of the first, hdhfr-selectable, knockout construct “Human-T-Cell 
nucleofector solution” was used. The second knockout construct (using tgdhfr as a 
selectable marker), as well as rescue and mock vector were transfected using 
“Parasite 2 nucleofector solution” which became available at that time.  
 
5.3.6.7 Transfection procedure 
For transfection, cells were pelleted by centrifugation (10s, 17,000g) and the 
supernatant discarded. Parasite pellets were immediately resuspended in 100μl of 
nucleofector solution containing 5-10µg DNA, prepared as described in section 5.2.5. 
The parasite-DNA-buffer solution was transferred to a cuvette and transfected using 
protocol U33 of the Amaxa® nucleofector device. Directly after electroporation 100μl 
of culture medium were added, and the solution was immediately injected into the tail 
vein of a CD1TM outbred mouse.  
 
5.3.6.8 Drug selection of transfected parasites 
Drug selection was facilitated by the resistance genes hdhfr or tgdhfr as parts of the 
plasmid vector (for a detailed description see section 5.2.1). Transfected parasites 
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were left without drug pressure for a period of 24h. For selection, transfected 
parasites were treated with pyrimethamine by administration of the drug to infected 
mice via the drinking water from day 1 to day 7. The drinking water was prepared 
from a 100x pyrimethamine stock-solution (pyrimethamine dissolved in DMSO to a 
final concentration of 7mg/ml) diluted with tap water (pH adjusted to 3.5-5.0, using 
5M HCl solution). According to the protocol, the drinking water was freshly prepared 
for each transfection (or in cases of prolonged treatment once weekly). 
For WR99210 selection, mice were injected subcutaneously with the drug on three 
consecutive days starting 24 hours after transfection (WR99210 injection solution: 
WR99210 dissolved in DMSO and diluted in a 70% DMSO, 30% H2O solution to a 
final concentration of 240µg/100µl). Per treatment 100µl of this solution/animal (with 
a bodyweight between 10 and 33g) was injected s.c.. 
 
5.3.7 Parasite Cloning 
Parasites were cloned by limiting dilution (Waters et al. 1997). Mice were inoculated 
so that the number of clones was Poisson-distributed with a mean λ ≤ 0.5, estimated 
by counting animals that did not develop parasitemia.  
Parasitemia and RBC count in blood with a parasitemia of ca. 1% were determined 
as described below, and blood was diluted in 160µl parasite medium to obtain ≤50% 
of animals that develop parasitemia after i.v. injection (generally, 2 microscopically 
detectable parasites per inoculum). Within 2 hours after calculating parasite numbers, 
parasite dilutions were injected i.v. into uninfected CD1TM outbred mice. 
Parasitemia was determined by counting at least 2,000 cells on a Giemsa-stained 
slide using a light microscope (staining protocol see section 7.3.3). The number of 
erythrocytes/µl blood was assessed using a Neubauer chamber. Prior to cell counting 
leucocytes were lysed by incubating 2µl of blood with 400µl Hayem´s reagent for 
5min. Subsequently, the chamber was filled, fluid allowed to settle for 5min, and cells 
within five big squares were counted. The total number of cells in five squares 
multiplied by 10,000 equates the number of erythrocytes/µl blood. 
 
5.3.8 In vivo growth assays 
For assessment of parasite growth rates mice were intravenously injected with 1000 
mixed blood-stage parasites. Parasite counting (parasitemia and RBC count) and 
 28
preparation was done as described for the cloning procedure. Following infection, the 
parasitemia of the animals was determined every 24 hours on Giemsa-stained blood 
smears (staining protocol see section 5.3.3). Survival times of the animals were 
recorded. Animals with definitive symptoms of cerebral malaria, such as seizures or 
torticollis or with severe prostration (inability to walk) were killed and recorded as 
death events. 
 
5.4 Molecular methods for assessment of parasite phenotypes 
5.4.1 Isolation of genomic DNA 
Genomic parasite DNA was extracted using the “QIAamp DNA Blood Mini Kit” 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The kit 
procedure comprises an initial lysis step, followed by DNA adsorption onto a silica-gel 
spin column and two subsequent washing steps. Finally, DNA is eluated under low 
salt conditions. 
If parasites were extracted from more than 200µl blood, saponin lysis was performed 
prior to extraction to avoid clogging of the column (for a description of the lysis 
procedure see section 5.4.7). For DNA extraction leucocytes were not removed from 
the blood. Parasite DNA was subsequently genotyped using the primers listed in 
table 2 (see even fig. 4). 
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Fig. 4: Generation of hslV-KO parasites and rescue/mock parasites. 
Horizontal arrows in A and C visualize the primer combinations listed in table 1. Homologous 
sequences for single/double crossover are marked in dark grey. 
(A) Upper row: linearized knockout constructs (first or second knockout), lower row: genomic hslV 
locus. Note that there is only one genomic hslV locus, i.e. parasites with a correctly integrated 
knockout construct at this locus do not contain the hslV sequence in their genome. 
(B) Upper two rows: linearized rescue and mock constructs, lower row: genomic locus for insertion (c-
ssurrna or d-ssurrna = small subunit ribosomal RNA gene of either c- or d-rrna unit). 
 
(C) Rescue and mock constructs after integration into genomic locus via single crossover.
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Table 2: Primers for transfection control 
Name Sequence Expected size of PCR product 
Primers for detection of the selectable markers in DNA of transfected parasites 
hdhfr for 5´ - GCATGGTTCGCTAAACTG – 3´ 
hdhfr rev 5´ - AATGCCTTTCTCCTCCTG – 3´ 
528bp 
tgdhfr for 5´ - AGAGGGGCATCGGCATCA – 3´ 
tgdhfr rev 5´ - TTGAAAGAATGTCATCTC – 3´ 
543bp 
Primers for detection of correct integration of knockout constructs 
hdhfr-5´Int for 5´ - GTTTATATGTGTGGATGTGTTTAC – 3´ 
hdhfr-5´Int rev 5´ - CTCGAAAAGAATTAAGCTGG – 3´ 
837bp 
hdhfr-3´Int for 5´ - TGATTCATAAATAGTTGGACTTG – 3´ 
hdhfr-3´Int rev 5´ - CCGTTGCATATTGGTGCTA – 3´ 
909bp 
tgdhfr-5´Int for 5´ - GTTTATATGTGTGGATGTGTTTAC – 3´ 
tgdhfr-5´Int rev 5´ - AATTATATGTTATTTTATTTCCAC – 3´ 
915bp 
tgdhfr-3´Int for 5´- AAATGTGGGGTAAAAAAGAGTG – 3´ 
tgdhfr-3´Int rev 5´- CCGTTGCATATTGGTGCTA – 3´ 
820bp 
Primers for detection of wild type DNA 
WT-locus for 5´- CCACGAAAACAAATAACCACAGC - 3´ 
WT-locus rev 5´- CCCGATCCTGTGCCTAAAAC – 3´ 
1KB 
Primers for detection of pfhslV-cDNA in rescue-transfected parasites 
pfhslV-cDNA for 5´- GGATCACAAAAATCAATAACC – 3´ 
pfhslV-cDNA rev 5´- CTGACATCCTCTTGATTAG – 3´ 
696bp 
Primers for detection of additional mock/rescue specific DNA sequences 
M/R-Ctrl for 5´- CTTGGAGCGAACGACCTAC – 3´ 
M/R-Ctrl  rev 5´- CGGAAGCATAAAGTGTAAAGC – 3´ 
586bp 
Primers for detection of integrated mock/rescue constructs 
M/R-5´Int for 5´- TTTGGATATTTTCATATATG – 3´ 
M/R-5´Int rev 5´- TTTCCCAGTCACGACGTTG – 3´ 
2.1KB 
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5.4.2 PCR analysis of genomic hslV locus in WT and transfected parasites 
All PCRs were done in a 50µl reaction volume containing the following components: 
5µl 10x PCR Buffer (Qiagen) 
10µl 5x Q-Solution (Qiagen) 
3µl 25mM MgCl2 (Qiagen) 
2µl dNTP mix (5mM each) 
1µl 10mM Forward Primer 
1µl 10mM Reverse Primer 
2.5µl Taq DNA polymerase (Qiagen) 
20-200ng template DNA 
Water (LiChrosolv®) up to 50µl 
 
5.4.3 Standard thermocycler settings 
(used with all primer combinations except mock/rescue integration-specific primers) 
95°C - 2min, (95°C - 30s, 55°C - 30s, 72°C - 60s, 30 cycles), 72°C 7min 
 
5.4.4 Thermocycler settings for mock/rescue integration-specific primers 
95°C – 2min 
(95°C – 30s, 50°C – 30s, 72°C – 150s, 20 cycles) 
(95°C – 30s, 50°C – 30s, 72°C – 150s + 1s time increment, 25 cycles) 
72°C – 7min 
 
All PCRs were validated for a “Primus 96 advanced” thermocycler from Peqlab. Other 
thermocyclers were used on occasions. Every PCR included positive and negative 
control samples. 
 
5.4.5 Sequencing of PCR products 
To confirm their identity, all the above-mentioned PCR products were sequenced as 
described in section 5.1.5. Sequences were confirmed at least once for every 
transfection and cloning experiment. 
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5.4.6 Preparation of parasite protein extracts 
Blood, containing the parasites, was obtained as described in section 5.3.4. and spun 
down (8min, 200g, RT). The erythrocyte pellet was mixed with an equal amount of 
PBS. Two volumes of a 0.15% saponin in PBS solution were added and erythrocytes 
were allowed to lyse for 5min at room temperature. Parasites were spun down 
(1,500g, 15min, 4°C), washed 3 times with 1ml ice-cold PBS (7,500g, 5min, 4°C), 
and dissolved in a suitable amount of Bäuerle buffer (20mM HEPES, 350mM NaCl, 
1mM MgCl2, 0.5mM EDTA, 0.1mM EGTA, 20% Glycerol (v/v), 1% Igepal CA-630, 1 
tablet protease inhibitor cocktail per 50ml final volume, stored at -20°C). Protein 
extracts were stored at -20°C. 
 
5.4.7 Western blotting 
For Western blotting parasite protein extracts were spun down (17,000g, 10min, 
4°C), and the supernatant was mixed with SDS loading buffer (filtered, aqueous 
solution containing 125mM Tris pH 6.8, 6% SDS, 20% glycerol, 0.2% bromophenol 
blue, 10% mercaptoethanol) to a final loading-buffer concentration of 1x. Samples 
were subsequently separated on a 12% SDS gel using the following gel and buffer 
mixtures: 
Stacking gel: 17% acryl/bis-acryl-amide (30%), 0.1875M Tris (pH6.8), 0.1% SDS, 
0.1% ammonium persulphate, 0.1% TEMED 
Resolving gel: 40% acryl/bis-acryl-amide (30%), 0.375M Tris (pH 8.8), 0.1% SDS, 
0.1% ammonium persulphate, 0.04% TEMED 
SDS running buffer: 250mM Tris, 1% SDS, pH8.3 
Proteins were blotted in semidry blotting buffer (48mM Tris, 39mM glycine, 0.037% 
SDS, 20% methanol pH 9.2) onto a nitrocellulose membrane (Bio-Rad, Art. No. 162-
0115) by applying a current of 1mA/cm2 for 60min. 
PbHslV (ClpQ) was visualized using a PfHslV-antiserum, diluted 1:2,000 (Mordmüller 
et al. 2006) as primary and “anti-rabbit IgG, HRP-linked Antibody”, diluted 1:2,000 
(Cell Signaling Technology) as secondary antibody. Proteins were visualized on a 
Chemi-Smart 5000 imaging system (Peqlab, Erlangen, Germany) using LumiGLO® 
chemiluminescence detection reagents (Cell Signaling Technology). 
To verify binding of all samples to the membrane, some blots were stripped and 
reprobed with an antibody against a proteasomal α-subunit (mAb MCP231 from anti-
proteasome α -subunit sampler pack, Biomol, Hamburg, Germany). Stripping was 
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done by incubation in stripping buffer (62.5mM Tris-HCl, pH 6.7; 2% SDS; 100mM β-
mercaptoethanol) for 30min at 50ºC. Detection of reprobed blots was done as 
described above, using “anti-mouse IgG, HRP-linked Antibody” (Cell Signaling 
Technology). 
 
5.4.8 Bio-Plex cytokine and chemokine assays 
Levels of selected cytokines and chemokines were determined in sera of three WT 
and three hslV-KO-infected CD1TM mice at the following time points: 
1 day prior to infection (baseline) and 3, 6 or 9 days after infection. 
Mice were infected with 1000 parasites as described for the parasite growth assays. 
Samples were stored at -20°C and then analyzed on a Bio-Plex® 200 system (Bio-
Rad) using a magnetic bead Bio-Plex Express Assay (Bio-Rad) with the following 
cytokines: IL-1α, IL-1β, IL-6, IL-12p40, IL-12p70, IFN-γ and MIP-1α. 
In a second experiment using 6 mice per group, the following cyto- and chemokines 
were additionally measured: IL-10, MIP-1β, Eotaxin, KC, MCP-1, Rantes, LIF, MIG, 
TNF-α and MIP-2. 
 
5.5 Further phenotyping methods 
5.5.1 Spleen-weight determination 
For a number of animals the spleen weight/body mass ratio was determined at time 
of death. For this purpose, spleens were dissected and spleens and animals weighed 
on a precision scale. 
 
5.5.2 Reticulocyte counts 
To determine a possible influence of the hslV-KO parasites on hematopoiesis, the 
ratio of polychromatic reticulocytes was determined on Giemsa-stained blood smears 
from WT and hslV-KO-infected CD1TM mice from three to six days post infection 
(staining protocol see section 5.3.3). 
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5.5.3 Cellular imaging 
To investigate possible differences in mitochondrial shape or size between knockout 
and wild type parasites, unfixed parasites were stained with the mitochondrial stain 
MitoTracker Red® and a DNA counterstain (Hoechst 33342), and subsequently 
assessed by flow cytometry (using a FACSCanto II cytometer) and fluorescence 
microscopy (using a Leica DMLB microscope). 
Parasites were stained for 30 min using the following dye concentrations: 
Hoechst 33342: 10µg/ml (FACS) and 0.033µg/ml (fluorescent microscopy) 
MitoTracker Red®: 0.5µM (FACS) and 2nM (fluorescent microscopy) 
 
5.5.4 Statistics 
Significance levels for differences in growth rates and reticulocyte counts were 
calculated by comparing the AUCs (areas under the curve) for WT and hslV-KO 
parasitemia / reticulocyte courses using Student’s two-tailed t-test. AUC values were 
determined by trapezoidal rule. For growth rates AUCs were obtained from the 
infection time point until either all WT or all hslV-KO-infected mice had died. Missing 
parasitemia values for animals dying prior to this endpoint were set as the last known 
value (LOCF method). For reticulocyte counts AUCs were obtained for the time frame 
investigated (three to six days post infection). 
Significance levels for survival times were determined by logrank test, since this test 
is the most commonly used test to compare survival curves (Schoenfeld 1981). 
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6 LIST OF REAGENTS 
 
Item Provider Art.-No. 
Acryl/Bis-Acryl-amide (30%) Sigma-Aldrich, Munich, 
Germany 
A2792-100ML 
Ammonium persulphate Amresco, Ohio, USA 04861-100g 
Bromophenol blue Sigma-Aldrich, Munich, 
Germany 
B0126-25G 
Disodium hydrogen phosphate 
dihydrate 
VWR International 
GmbH, Darmstadt, 
Germany 
28.029.292 
Ethylenediaminetetraacetic acid 
(EDTA) 
Merck, Darmstadt, 
Germany 
100944 
Ethylenediaminetetraacetic acid 
(EDTA) calcium disodium salt 
Sigma-Aldrich, Munich, 
Germany 
ED25C-100G 
Ethylene glycol tetraacetic acid 
(EGTA)  
Sigma-Aldrich, Munich, 
Germany 
E3889-100G 
Gentamicin, liquid, 50 mg/ml Invitrogen, Karlsruhe, 
Germany 
15750-037 
Giemsa’s azure eosin methylene 
blue solution 
Merck, Darmstadt, 
Germany 
1.09204.1000 
Foetal Bovine Serum GOLD PAA Laboratories, 
Cölbe, Germany 
A15-151 
Glycerol, purum, anhydrous Sigma-Aldrich, Munich, 
Germany 
49780-1L 
Glycine Roth, Karlsruhe, 
Germany 
3908.2 
L-Glutamine solution, 200 mM Sigma-Aldrich, Munich, 
Germany 
G7513 
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Item Provider Art.-No. 
Hayem´s reagent Merck, Darmstadt, 
Germany 
1.09260 
HEPES solution, 1M Sigma-Aldrich, Munich, 
Germany 
H0887 
Histodenz™ powder Sigma-Aldrich, Munich, 
Germany 
D-2158 
Hoechst 33342 Invitrogen, Karlsruhe, 
Germany 
H1399-100mg 
IGEPAL® CA-630 Sigma-Aldrich, Munich, 
Germany 
13021 
LiChrosolv®, Water for 
chromatography 
Merck, Darmstadt, 
Germany 
1.15333.2500 
Liquemin N5000 Roche, Grenzach, 
Germany 
PZN 3441118 
β-Mercaptoethanol Sigma-Aldrich, Munich, 
Germany 
63689 
Methanol Merck, Darmstadt, 
Germany 
1.06009.2511 
MitoTracker Red® CMX Ros Invitrogen, Karlsruhe, 
Germany 
M7512 
Potassium chloride Merck, Darmstadt, 
Germany 
104936 
Potassium dihydrogen phosphate Merck, Darmstadt, 
Germany 
30.06.06 
Protease Inhibitor Cocktail Tablets Roche, Grenzach, 
Germany 
11697498001 
Pyrimethamine powder Sigma-Aldrich, Munich, 
Germany 
P7771 
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Item Provider Art.-No. 
RPMI-1640 Medium with NaHCO3 Sigma-Aldrich, Munich, 
Germany 
R0883 
SDS ultrapure Roth, Karlsruhe, 
Germany 
2326.2 
TEMED Roth, Karlsruhe, 
Germany 
2367.3 
Trizma® Base Sigma-Aldrich, Munich, 
Germany 
T1503 
WR99210 JACOBUS 
PHARMACEUTICAL 
COMPANY, INC., 
Princeton, NJ, USA 
N/A 
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7 RESULTS 
7.1 hslV-KO parasites are viable in the murine host 
To assess the essentiality as well as possible functions of hslV, hslV-deficient P. 
berghei-parasites were generated. The knockout was achieved by transfection of two 
different knockout constructs, containing hdhfr as selectable marker sequence for the 
first knockout and the tgdhfr selectable marker sequence for the second knockout. 
The second knockout, containing tgdhfr as a selectable marker was generated to 
facilitate the cotransfection of a hdhfr-containing rescue construct, by selection of the 
hslV-KO-transfected parasite population with pyrimethamine and the rescue-
transfected parasite population with the antimalarial WR99210 as described in 
section 5.3.6. 
Following the transfection procedure, parasites were cloned, which led to six 
independent knockout clones with correctly integrated hdhfr construct for the first 
knockout and two clones with correctly integrated tgdhfr construct for the second 
knockout. Correct integration of the transfected sequences was assessed by PCR 
using the primers provided in the first three sections of table 2 (section 5.4.1). The 
location of these primers is given in fig. 4. In case of successful transfection the 
primers for detection of the used selectable marker sequence (tgdhfr or hdhfr) should 
yield a PCR product of ca. 550bp length, whereas the 5´- and 3´-integration-specific 
primers for the knockout constructs should yield PCR products of ca. 900bp length.  
The WT locus-specific primers should yield a 1KB long PCR product only in wild type 
parasites. All PCRs resulted in products of the expected sizes. PCR products were 
only detectable using DNA extracts containing the sequences targeted by the 
respective primers (for a representative PCR result see fig. 5). 
The identity of all PCR products was additionally confirmed by sequencing following 
each transfection or cloning experiment. 
Obtained results, as depicted in fig. 5, demonstrate that the transfected hslV-KO 
sequence integrated into the hslV locus and that no residual WT parasites were 
present in the clonal parasite populations. 
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Fig. 5: Agarose gel showing PCR results that confirmed correct integration of the first knockout 
construct (containing hdhfr as a selectable marker) in three parasite clones. Note that the hslV-WT-
locus is no longer detectable in the knockout parasites. 
Upper labels indicate the used template DNA (Neg. = negative control), lower labels refer to the used 
primer sets. hdhfr-5´Int and hdhfr 3´Int primers span the integration site at the 5´UTR and 3´UTR of the 
hslV locus. In case of correct integration the PCR yields integration-specific PCR products of 837bp 
(5´UTR) and 909bp (3´UTR) length respectively, whereas no PCR product is expected in 
untransfected WT parasites. The WT locus-specific PCR in contrast targets the hslV sequence, which 
is replaced by the integrating DNA during double crossover, therefore amplification of the 1KB long 
PCR product is only expected in WT parasites, but not in hslV-KO parasites. Results show that all 
PCR products have the expected sizes and do occur in the expected parasite lines, i.e. integration-
specific PCR products occur only in hslV-KO parasites and WT-locus PCR products occur only in WT 
parasites.
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7.2 hslV-KO parasites do not express ClpQ 
The hslV expression level was determined by Western blot analysis of parasite 
protein extracts of hslV-KO and WT parasites using an α-PfHslV-antiserum 
(Mordmüller et al. 2006). Cross reactivity of the α- PfHslV serum with PbHslV was 
initially confirmed by comparing blotting results of P. falciparum and P. berghei 
protein extracts. On Western blot HslV appears as two distinctive bands at 18 and 23 
kDA (corresponding to the processed (active) and unprocessed form of the 
protease), which are always detectable in unsynchronized WT parasites. As 
expected, cloned knockout parasites showed no residual hslV expression (see fig. 6). 
 
Fig. 6: Blotted extracts of hslV-KO and WT parasites. 
Upper panel: 
Three P. berghei hslV-KO and two P. berghei WT extracts probed with anti-PfHslV. The right picture 
shows a blotted P. falciparum WT extract for comparison [picture derived from (Mordmüller et al. 
2006)]. The two bands correspond to the unprocessed form of PbHslV (23kDa) and the mature 
protease (17kDa). 
Lower panel (loading control): 
Same blot stripped and reprobed with mAb MCP231, an antibody recognizing the α-subunit of the 
proteasome, confirming the presence of sample in all lanes. 
7.3 PbHslV (ClpQ) deletion leads to growth retardation of asexual 
parasite blood stages and alters the survival time of the host  
To assess the fitness of the ClpQ-deficient parasites, mice of three different strains 
were intravenously infected with 1000 WT- or hslV-KO-parasites, respectively, 
followed by daily parasitemia counts on Giemsa stained thin blood smears. The 
investigation of growth rates in three different mouse strains was motivated by the 
finding of a significantly slower growth rate of the hslV-KO-parasites in CD1TM 
(outbred) mice. To further evaluate the importance of this finding the experiment was 
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repeated with the two immunologically distinct inbred mouse strains C57BL/6 and 
BALB/c. C57BL/6, a cerebral malaria susceptible mouse strain, is believed to mount 
a Th1 dominated immune response, whereas the cerebral malaria resistant BALB/c 
mouse seems to mount a more Th2 dominated immune response (Mills et al. 2000). 
These in vivo parasite growth assays revealed a significantly slower growth (i.e. 
parasitemia development over time) of ClpQ-deficient parasites, compared to WT 
parasites. The observed growth retardation was significant for all three mouse strains 
used (CD1TM mice, p < 0.001, C57BL/6 mice, p = 0.01, and in BALB/c mice, p < 
0.001; see fig. 7). Assays in CD1TM mice were conducted with parasites of three 
different knockout clones and growth retardation was evident for parasites of all three 
clones.
 
Fig. 7: Course of parasitemia in hslV-KO- and WT-infected animals in different mouse strains. 
(A) Median parasitemia of 9 WT and 6 hslV-KO-infected animals (CD1TM mice), 6 mice per parasite 
line (BALB/c), and 5 mice per parasite line (C57BL/6). 
(B) Parasitemia course in the same mice per animal. Discontinued lines prior to end of time axis 
represent animal deaths. 
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Besides its effect on growth, PbHslV deletion had a significant impact on survival 
times of infected mice: CD1TM and C57BL/6 mice, infected with hslV-KO parasites, 
survived significantly longer than WT-infected animals, whereas hslV-KO-infected 
BALB/c mice had a shorter survival time than WT-infected BALB/c (see fig. 8). 
 
 
Fig. 8: Kaplan-Meier plots depicting survival times of three different mouse strains following infection 
with hslV-KO parasites (first knockout) or WT parasites.  
Note the reverse correlation of hslV-KO genotype and survival times in BALB/c mice compared to 
CD1TM and C57BL/6 mice. n = total number of animals per curve. Small vertical lines indicate 
censored animals (death not associated with malaria), digits represent the number of censored 
animals. 
Differences in survival time were significant in all comparisons (logrank test, p < 0.001 for CD1TM, p < 
0.01 for BALB/c, and p < 0.05 for C57BL/6 mice).  
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7.4 Parasite growth retardation can be rescued by cotransfection 
of pfhslV into a separate genomic locus 
To show that hslV itself caused the observed growth retardation, hslV-KO parasites 
were cotransfected with pfhslV, i.e. a single crossover construct containing the P. 
falciparum cDNA sequence was transfected. This vector was designed to integrate 
into either the c- or d-ssurrna gene. To control for phenotypic effects caused by this 
integration event or by the selective drug treatment, a mock-transfected parasite line 
was generated. Mock parasites were transfected with a modified rescue construct 
lacking the pfhslV-cDNA sequence. DNA extracts of rescue- and mock-transfected 
parasites were analyzed by PCR using all primers listed in table 2 (section 5.4.1). 
PCR analyses using these primers allow to determine the genotype of the different 
parasite lines (WT, hslV-KO, rescue and mock) by comparison of the resulting PCR 
products, as shown in fig. 4. Primer pairs targeting the selectable marker sequences 
hdhfr and tgdhfr only yielded PCR products in transfected parasite lines containing 
those sequences, integration-specific primer pairs only yielded PCR products in case 
of successful 3´- or 5´-integration of the transfected DNA into the targeted locus. WT-
locus primers only yielded a PCR product in WT parasites with an intact hslV locus, 
whereas in knockout parasites no product was detected. The pfhslV-cDNA primers 
only amplified a PCR product in rescue-transfected parasites, whereas the M/R-
control primers targeted a sequence present within both the mock and the rescue 
vector. 
PCR results showed that both mock and rescue constructs integrated correctly into at 
least one of the genomic c-ssurrna or d-ssurrna loci and all PCR products had the 
expected sizes, i.e. ca. 550bp for the selectable marker sequences and for the M/R-
control-PCR, 700bp for the hslV-cDNA sequence, 1KB for the WT-specific PCR, and 
2.1KB for the mock/rescue integration-specific PCR (see fig. 9 for a representative 
PCR result).  
The identity of all PCR products was additionally confirmed by sequencing following 
each transfection or cloning experiment. 
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Fig. 9: Agarose gel showing PCR results for the transfection control of cloned parasite lines.  
Upper labels indicate the used template DNA (M = Mock, R = Rescue, KO = tgdhfr-KO, WT = wild 
type, N = negative control), lower labels refer to the used primer sets. 
The results confirmed the correct integration of transfection constructs. The M/R-specific sequence 
and the selectable marker for the mock and rescue parasites (hdhfr) are only detectable in DNA 
extracts of mock and rescue parasites. The selectable marker for the knockout, which even is present 
after mock or rescue cotransfection, is detectable in all transfected parasite lines, but not in WT 
parasites, whereas the sequence of the genomic hslV-locus is only detectable in WT parasite extracts. 
 
Western blot analyses of protein extracts of cloned mock and rescue parasites 
confirmed restored expression of ClpQ in its processed (active) and unprocessed 
form in the rescue parasites and lacking ClpQ expression in the mock parasites (see 
fig. 10). 
 
 
Fig. 10: Blotted extracts of different parasite lines probed with anti-PfHslV. 
Upper bands represent a 28kDa-cross-reaction, which is occasionally detected by the PfHslV-
antiserum in WT as well as in hslV-KO parasites. 
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In mice, treated with the antimalarial drug WR99210, growth rates of rescue-
transfected parasites were significantly higher than those of mock-transfected 
parasites (p < 0.001), comparable to the relation of growth rates of WT and hslV-KO 
parasites in untreated mice (see fig. 11). The WR99210-treatment was necessary to 
prevent reversion of rescue and mock lines to the parental genotype (hslV-KO), since 
the cotransfected rescue and mock constructs, in contrast to the stably integrated 
knockout construct, were integrated by single-crossover and could therefore be lost 
again in the absence of drug pressure (Thathy and Ménard 2002). 
 
 
Fig. 11: Growth rates of WT and hslV-KO (left panel) vs. rescue- and mock-transfected parasites (right 
panel). 
Growth rates were determined in CD1TM mice. A: median parasitemia values for 6 - 10 animals per 
curve, B: individual parasitemia values for those animals (note that out of 6 mock-infected mice only 3 
did develop a detectable parasitemia). hslV-KO growth rates differ from fig. 7 since those data refer to 
first knockout line transfected with hdhfr and here to the second line transfected with tgdhfr. 
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Survival times of hslV-KO and mock-infected mice were significantly prolonged 
compared to the survival times of WT- or rescue-infected mice, respectively (see fig. 
12). 
 
Fig. 12: Kaplan-Meier plot depicting survival times of CD1TM mice infected with four different parasite 
lines. n = total number of animals per curve. Small vertical lines indicate censored animals (death not 
associated with malaria), digits represent the number of censored animals. All alterations in survival 
times were significant (logrank test, p < 0.001 for WT vs. hslV-KO and p < 0.05 for rescue vs. mock). 
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7.5 Similar growth of WT and hslV-KO parasites in MyD88-KO mice. 
To test a potential involvement of TLR-mediated processes in the observed growth 
retardation, the growth assays were repeated using MyD88-KO mice on the 
background of C57BL/6. Since MyD88 is a downstream mediator molecule of all 
murine TLRs except TLR 3, MyD88-deficient mice can be regarded as a model for 
TLR non-functionality. In MyD88-deficient mice hslV-KO parasites grew at a similar 
rate as WT parasites, and differences in growth were no longer significant (p = 0.1). 
Median survival time of hslV-KO-infected MyD88-KO mice was two days shorter 
compared to WT-infected MyD88-KO mice, and this observation was significant (p < 
0.01), (see fig. 13). Irrespective of the infecting parasite line, MyD88-KO mice 
survived about 10 days longer than intact C57BL/6. 
 
Fig. 13: Course of parasitemia and survival rates of hslV-KO and WT-infected MyD88-KO mice 
(genetic background C57BL/6). 
(A) Median parasitemia of eight WT and six hslV-KO (first knockout) infected MyD88-KO mice. 
(B) Individual parasitemia courses for the animals from A. 
(C) Kaplan-Meier plot depicting survival times of MyD88-KO mice following infection with hslV-KO 
parasites - first knockout (interrupted lines) and WT parasites (continuous lines). Small vertical lines 
indicate censored animals (death not associated with malaria), digits represent the number of 
censored animals.  
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7.6 Results of first physiological and immunological investigations 
7.6.1 Intact C57BL/6 mice infected with hslV-KO parasites have an increased 
spleen weight. 
It is known that P. berghei-infected mice develop a considerable splenomegaly during 
the course of the disease, which is partly caused by proliferation of the red pulp and 
even more by proliferation of the splenic lymphoid tissue, the white pulp (Eling et al. 
1977, Freeman and Parish 1978). Therefore, post-mortal spleen weight of hslV-KO- 
and WT-infected animals was determined as a first indicator of immunologic 
responses of the host’s immune system. 
Post-mortal spleen weight determination in three WT-infected and five hslV-KO-
infected C57BL/6 mice revealed a significantly higher spleen weight/body weight ratio 
for the knockout animals, p = 0.003, as calculated by t-test (see fig. 14). 
Spleen-weight measurements in CD1TM and BALB/c mice showed no differences 
between WT- and hslV-KO-infected animals. 
 
 
Fig. 14: Post-mortal spleen weight in C57BL/6 (5 hslV-KO and 3 WT-infected mice). 
Grey bars represent mean spleen weight as percent of body weight, small squares represent mean 
bodyweight of the animals (error bars indicate double standard deviations). Sampling time points: WT 
3x 9 days post infection, hslV-KO = 2x 9 and 3x 10 days post infection. 
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7.6.2 White blood cell counts do not differ significantly between hslV-KO and 
WT parasites. 
To investigate the host’s immune response further for possible changes caused by 
the altered genotype of the knockout parasites, white blood cell (WBC) populations in 
peripheral blood of hslV-KO- and WT-infected animals were measured at three 
consecutive time points. For WT parasites it was expected to see a drop in peripheral 
WBC counts at 2-4 days post infection. In own experiments WT- as well as hslV-KO-
infected mice showed a transient drop in peripheral leukocyte counts at two days 
post infection. This leucopenia was due to a simultaneous decrease of all WBC 
populations measured (lymphocytes, monocytes and granulocytes), but there were 
no apparent differences between WT- and hslV-KO-infected animals (see fig. 15). 
 
 
Fig. 15: WBC numbers measured in six WT and twelve hslV-KO-infected CD1TM mice prior to 
infection, and two and six days post infection. Bars and error bars (= 2x standard deviation) represent 
mean total WBC values, bar sections the fractions of WBCs as indicated in the legend.
7.6.3 Reticulocyte counts do not differ significantly between hslV-KO and WT 
parasites. 
In accordance with results of other researchers (Maggio-Price et al. 1985) 
reticulocyte counts of WT and hslV-KO-infected mice approximately doubled between 
day three and six post infection, but values indicated no differences between hslV-
KO and WT parasites (see fig. 16). 
 
 
Fig. 16: Reticulocyte counts during the course of WT and hslV-KO infections do not differ significantly 
(p = 0.29). 
 
7.6.4 Serum cytokine and chemokine levels do not differ significantly between 
hslV-KO and WT parasites. 
To further characterize the immune response of the host, changes in cytokine and 
chemokine levels were determined in the sera of WT- and hslV-KO-infected mice 
prior to infection and three, six and nine days post infection. As described in the 
literature, it was expected to see an upregulation of proinflammatory cytokines, such 
as IFN-γ and TNF-α during early stages of infection (Hanum et al. 2003, Stevenson 
and Riley 2004). However, own results showed no clear trends of cytokine regulation 
in the obtained serum samples and no significant differences between WT- and hslV-
KO-infected animals (see fig. 17). 
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7.6.5 Mitochondrial DNA of WT and hslV-KO parasites show distinct 
MitoTracker staining patterns 
Since previous experiments showed that hslV of P. falciparum is located within the 
mitochondrion (Tschan et al. 2010), the mitochondrial phenotype of WT and hslV-KO 
P. berghei parasites was investigated by Mitotracker-staining. MitoTracker Red is a 
red fluorescing dye that accumulates within the mitochondrion. Here it was used to 
compare shape and structure of the plasmodial mitochondria between hslV-KO and 
WT parasites. To visualize the nuclei of the parasites, samples were counterstained 
with the DNA-staining dye Hoechst 33342. Stained hslV-KO parasites showed 
distinct Mitotracker aggregations, which were not evident in WT parasites (see fig. 
18). The reason for this altered mitochondrial shape remains to date unclear. 
 
 
Fig. 18: Mitotracker staining of WT and hslV-KO parasites 
 
Attempts to quantify these effects by flow cytometric assessment of MitoTracker 
stained parasites were not successful due to different parasite stages in mixed blood 
stage infections.  
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8 DISCUSSION 
8.1 hslV deficiency in P. berghei leads to the phenotype “retarded 
growth” 
Experiments in this thesis should clarify, whether the threonine peptidase ClpQ of P. 
berghei is essential for the parasite, and if possible, to further characterize its 
function. To achieve this goal hslV-KO parasites were generated. If proven to be 
essential for the parasite, hslV would have been a candidate gene for drug targeting. 
The fact that the hslV-KO parasites were viable, shows that ClpQ is not essential for 
the development of P. berghei in its murine host. Although this finding suggests that 
hslV probably is not suitable as a drug target, the observed phenotype of the 
knockout parasites still was interesting in view of a functional characterization of 
ClpQ. 
The in vivo growth assays showed that hslV-deficient P. berghei parasites have a 
distinct phenotype, i.e. significantly reduced growth rates of the asexual blood 
stages. Growth rates were determined by daily parasitemia counts during controlled 
WT- and hslV-KO-infections. The growth retardation was evident in all three mouse 
strains investigated (CD1TM, BALB/c and C57BL/6 mice). Observed growth rates for 
WT parasites in C57BL/6 and BALB/c mice were in accordance with previously 
published reports (Griffith et al. 2007, Hanum et al. 2003), while for CD1TM mice no 
comparable data exist. 
Rescue transfection of the Plasmodium falciparum hslV-cDNA-sequence led to 
restored expression of both pre-processed and active form of hslV (see fig. 10). This 
was expected due to the high degree of homology between different plasmodial 
species (Mordmüller et al. 2006) and indicates that the rescue parasites express a 
functional form of ClpQ. 
The reversal of the observed growth retardation in rescue-transfected parasites, 
caused by the insertion of hslV into a completely different genomic locus, 
demonstrated that the protease itself is responsible for this phenotype. The insertion 
of transfection constructs into the c- or dssurrna locus has previously been shown not 
to influence parasite growth rates (Franke-Fayard et al. 2004). This is not surprising, 
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considering the fact that c- and dssurrna is believed to be transcribed exclusively 
during mosquito stages (van Spaendonk et al. 2000). 
Rescue-transfected parasites had significantly higher growth rates than mock-
transfected parasites. It is likely that growth rates of both rescue and mock-
transfected parasites were delayed by WR99210 treatment of the mice. De Koning-
Ward et al. (2000a) report that the WR99210 resistance of hdhfr-transfected 
parasites is related to the hdhfr copy number, and that a single copy of hdhfr only 
slightly increases WR99210 resistance compared to tgdhfr, which was used as 
selectable marker for the knockout. They claim that the IC50 of WR99210 for a single 
copy of tgDHFR is 3 x 10-9, while the IC50 of WR99210 for a single copy of hDHFR is 
5 x 10-9. Such a minimal increase in resistance against the selective treatment makes 
an influence of this treatment on parasite multiplication rates likely. For this reason I 
did not compare absolute parasite growth rates of WT and rescue parasites, but their 
respective relationship to the hslV-deficient parasite line undergoing the same 
treatment (WT vs. hslV-KO and rescue vs. mock), which showed in both cases that 
the hslV-deficient parasites grew significantly slower than parasites expressing hslV 
(see fig. 11). 
8.2  PbHslV / ClpQ expression influences survival time of the host 
CD1TM and C57BL/6 mice infected with hslV-KO parasites survived significantly 
longer than WT-infected animals, whereas hslV-KO-infected BALB/c mice had a 
shorter survival time than WT-infected BALB/c (see fig. 8). Strikingly, one out of three 
hslV-KO-infected BALB/c mice showed clear neurological symptoms, i.e. ataxia and 
seizures, prior to death. Usually BALB/c mice do not develop experimental cerebral 
malaria (ECM). The triggering of this clinical picture in otherwise ECM resistant 
animals caused by hslV deficiency of the infecting parasites indicates that hslv 
deficiency may lead to changes in pathogenesis. 
Griffith et al. (2007) showed in C57BL/6 mice that MyD88 deficiency confers 
protection against a P. berghei infection, whereas in P. berghei-infected BALB/c 
mice, MyD88 deficiency leads to shortened survival times of infected animals and to 
the development of ECM. Their results in conjunction with the own finding of 
development of ECM in hslV-KO-infected BALB/c mice motivated me to investigate a 
possible interaction of parasite-hslV with host-MyD88 or TLRs. 
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8.3  Interaction of parasite and innate immune response as a 
possible explanation for the growth retardation of hslV-
deficient parasites 
The altered growth characteristics of hslV-deficient parasites could either be 
explained by a parasite intrinsic factor or implicate an interrelation of hslV and the 
host’s innate immune system. 
A fact suggesting immune-mediated growth retardation is the increased spleen 
weight in hslV-KO-infected C57BL/6 mice. Generally, P. berghei-infected mice 
develop a marked splenomegaly during the course of infection (Eling et al. 1977). 
The spleen is of key importance for the host’s resistance against malaria. It is the 
major site for removal of parasitized erythrocytes, for generation of immunity and for 
adaptive hematopoiesis (Engwerda et al. 2005). Spleen weight in hslV-KO-infected 
C57BL/6 mice was increased, while parasitemia developed more slowly compared to 
WT-infected mice. This could be related to an enhanced protective immune response 
or to sequestration of WBCs with unfavorable immune functions in the spleen caused 
by the hslV-KO parasites. An enhanced immune response in hslV-KO-infected mice 
in turn would suggest an immunosuppressive role of hslV or possibly of downstream 
mediator molecules. The fact that a significant spleen weight increase was only 
observed in hslV-KO C57BL/6 mice, but not in BALB/c or CD1TM outbred mice could 
imply that this spleen weight increase was mediated by Th1 type immune 
mechanisms, since C57BL/6, in contrast to BALB/c mice, are believed to mount a 
Th1 dominated immune response (Mills et al. 2000). 
 
8.4  Proposed interaction of hslV and MyD88/TLR-signaling 
The innate immune system generally senses PAMPs of invading pathogens through 
PRRs, which therefore represent potential interaction partners of plasmodial PAMPs. 
In mammals, Toll-like receptors (TLRs) are the major PRR subgroup. As outlined 
above, the phenotyping results suggested possible interactions between hslV or a 
hslV-derived molecule and TLRs/MyD88. Such an interaction could indicate that hslV 
represents a plasmodial PAMP. As outlined in section 3.4.4, knowledge about 
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plasmodial PAMPs is still insufficient. This led to the investigation of TLR involvement 
in host parasite interactions by comparing parasitemia development of WT and hslV-
KO parasite infections in MyD88-KO mice (see fig.13). 
In MyD88-deficient mice, which are regarded as a model for TLR non-functionality, 
growth retardation of hslV-KO parasites compared to WT parasites was not evident. 
This led to the hypothesis that a linkage of hslV-mediated signaling of the parasite 
and Toll-like receptor signaling of the murine host improved growth conditions for the 
invading parasite. These beneficial growth conditions were not present in hslV-
deficient parasites or in a MyD88-deficient host, which would explain the lower 
parasite growth rates under either of those conditions (see fig. 19). 
An additional finding was that growth rates of WT (but not of hslV-KO) parasites were 
considerably higher in normal than in MyD88-deficient C57BL/6 mice. This result 
further supports the hypothesis of an hslV-TLR-mediated parasite growth promotion, 
but is in contrast to the results of Griffith et al. (2007) and Coban et al. (2007b), who 
report a similar parasitemia development in normal and MyD88-deficient C57BL/6 
mice. It is possible that the here observed differences between normal and MyD88-
KO mice were caused by differences between the C57BL/6 lines used, since normal 
C57BL/6 were obtained from Charles-River-Laboratories and MyD88-deficient 
C57BL/6 from the MPI, Berlin. For this reason differences were not further evaluated. 
However, the growth rates of WT parasites in MyD88-KO mice depicted in fig. 13 
were reproducible, since the eight WT-infected MyD88-KO mice were infected on two 
different days with comparable results. 
In summary, growth rates of WT and hslV-KO parasites in MyD88-KO mice suggest a 
linkage of parasite-hslV and host-TLR-signaling. Specific TLRs or TLR-expressing 
cell types, which could be involved in such an interaction, remain elusive. There are 
several publications reporting an inhibition of DC maturation, caused by malaria 
parasites, which are discussed in section 8.7. 
8.5  Possible hslV interactions I: The chaperone network of the 
mitochondrial matrix 
How an immune interaction between hslV and TLR-signaling could be mediated 
needs further clarification. Our group recently showed that ClpQ is located within the 
mitochondrion (Tschan et al. 2010). Furthermore results of the MitoTracker-staining 
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show that mitochondria appear to have a different shape in hslV-KO as in WT P. 
berghei parasites. Analogously it was reported for trypanosoma that RNAi 
knockdown of trypanosomal hslV markedly altered mitochondrial DNA replication, 
leading to a continuous synthesis of small circular mitochondrial DNA and growth of 
the mitochondrial DNA complex to an enormous size (Li et al. 2008). 
Regarding this mitochondrial localization it seems unlikely that ClpQ is exported to 
the iRBC surface. It rather suggests that host parasite-interactions either are 
mediated by downstream mediators of hslV or that the protease is liberated during 
schizont egress (see fig. 19). 
One possible explanation for an interaction between ClpQ and the host’s immune 
system could be an exported mediator-molecule processed by ClpQ. In this context it 
is interesting that Ginsburg (website reference) published a chaperone network of the 
mitochondrial matrix, which facilitates the cleavage of imported proteins within the 
mitochondrion and their subsequent export as peptides. It is known that several heat-
shock proteins are part of this network. Therefore, it is tempting to speculate that hslV 
could be part of this network. 
 
 
Fig. 19: Proposed interaction of hslV-mediated and TLR-mediated signaling. 
hslV may be part of a parasite signaling pathway that activates host TLRs, thereby provoking a switch 
in the host’s innate immune response, which supports parasite growth. 
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8.6  Possible hslV interactions II: The innate immune system 
Another possible function of hslV could be fulfilled during schizont egress. This 
hypothesis is supported by the exclusive expression of ClpQ during late parasitic 
stages (late trophozoites and schizonts). An interference with immune functions 
during this period could facilitate an easier invasion of new RBCs by the released 
merozoites. An impairment of this mechanism would in turn lead to lower invasion 
rates thereby explaining the growth retardation of hslV-KO parasites. 
Ockenhouse et al. (2006) and McCall et al. (2007) used microarrays to investigate 
PBMC gene-expression profiles during presymptomatic and clinically apparent P. 
falciparum infection. They found an upregulation of several TLRs, MyD88, NF-κB, 
and IFN-γ in clinically apparent as well as in presymptomatic infections. Similarly, 
Ropert et al. (2008) describe an initial upregulation of MyD88/TLR-signaling and 
proinflammatory cytokines in experimental murine malaria. They concluded that 
MyD88-signaling could be associated with malaria pathogenesis, which fits to the 
observation of prolonged survival in MyD88-KO mice. Even previous studies with P. 
berghei-infected MyD88-KO mice supported the finding that MyD88-deficiency of the 
host leads to prolonged survival after infection (Griffith et al. 2007, and Coban et al. 
2007b), although these authors did not find any influence of MyD88-deficiency on 
parasitemia. 
Taken together, results from the cited publications suggest that the MyD88/TLR-
mediated immune response during early, presymptomatic infection has a detrimental 
effect on the host. If one assumes an interaction between hslV and MyD88/TLR 
signaling, such an effect could explain the growth retardation of hslV-KO parasites as 
well as that of WT parasites in MyD88-deficient mice. 
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8.7  Possible interactions between TLRs and iRBCs 
The pathways through which iRBCs and TLRs could interact, still remain elusive. 
Urban et al. (2001) found a parasite-mediated inhibition of DCs, which subsequently 
fail to fully activate T cells and shift cytokine secretion from a Th1 type to a Th2 type 
pattern. They report that DC inhibition is mediated by CD36 and caused by intact 
iRBCs only, whereas a lysate of iRBCs has no effect, which contradicts the 
hypothesis of hslV liberation during schizont egress. Own experiments showed no 
differences in serum cytokine levels between hslV-KO- and WT-infected mice. This 
does not generally exclude the presence of distinct cytokine expression patterns as 
described in this publication. Differences could be restricted to certain cell types, 
such as splenocytes or certain WBCs or could become evident only after 
investigation of larger animal numbers or other time frames. hslV-mediated DC 
inhibition by parasitized erythrocytes can therefore be regarded as one possible 
interaction between hslV and the immune system. 
TLR-iRBC-interactions could be mediated by surface proteins exported to the surface 
of the iRBC, which in turn could be processed by hslV. Chitnis (2001) reports that the 
AMA-1 protein of plasmodia is proteolytically processed at the time of schizont 
rupture, facilitating its expression on the merozoite surface. Since it was not possible 
to knock out the ama-1 gene, it is assumed that AMA-1 has an essential function 
during invasion. Further proteins, related to erythrocyte invasion stated in the same 
publication include RBPs (reticulocyte binding proteins) and EBPs (erythrocyte 
binding proteins). EBPs have been shown to be linked to the level of virulence of 
different P. yoelii strains [reviewed by Culleton and Kaneko (2009)]. They state that a 
mutation within the P. yoelii Erythrocyte Binding Like (PyEBL) protein leads to an 
altered trafficking pathway of this protein (i.e. to the dense granules instead of the 
micronemes), which subsequently leads to highly increased multiplication rates of the 
asexual blood stages. Whether or not these molecules are related to hslV, requires 
further clarification. 
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9 SUMMARY 
The protease ClpQ, encoded by the plasmodial gene hslV (PB000649.02.0),  
is a threonine peptidase, expressed by plasmodia during the late blood 
stages. Due to its highly conserved sequence among Plasmodium spp., hslV 
appears to play a fundamental role in plasmodial cell metabolism. This thesis 
investigates its function by generation and phenotypic characterization of 
transgenic, hslV-deficient Plasmodium berghei parasites. hslV-deficient 
parasites showed a substantial growth retardation of the blood stages, which 
was partially reversed when MyD88-deficient mice were used as a host 
organism. 
An explanation for this phenomenon could be a linkage of hslV-mediated 
signaling of the parasite and Toll-like receptor signaling of the murine host, 
which leads to improved growth conditions for the invading parasite. These 
beneficial environment is probably not provided in hslV-deficient parasites or 
in a MyD88-deficient-host explaining the lower parasite growth rates under 
those conditions. How these host-parasite-interactions are mediated, is 
subject of further investigations. 
In summary, the obtained results suggest that the protease ClpQ may be 
involved in the modulation of the host’s innate immune response during an 
infection with Plasmodium berghei, which suggests that ClpQ is a candidate 
for a plasmodial virulence factor. Its absence in the mammalian host makes 
ClpQ an attractive target for future interventional approaches. Further 
research to characterize related molecular pathways is needed to clarify its 
role during the innate immune response especially in view of future vaccine 
development strategies. 
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10 ZUSAMMENFASSUNG 
Die Protease ClpQ, die durch das plasmodiale Gen hslV (PB000649.02.0) 
kodiert wird, ist eine Threoninpeptidase, die von späten Blutstadien der 
Plasmodien exprimiert wird. Aufgrund seiner in Plasmodium spp. 
hochkonservierten Sequenz, scheint hslV für den Zellstoffwechsel der 
Parasiten von grundlegender Bedeutung zu sein. In dieser Arbeit wurde die 
Funktion von ClpQ anhand eines hslV-Knockouts in Plasmodium berghei und 
nachfolgender Phänotypisierung der Knockout-Parasiten untersucht. hslV-
defiziente Parasiten zeigten erheblich reduzierte Vermehrungsraten der 
Blutstadien. Dieser Phänotyp war bei der Infektion von MyD88-Knockout-
Mäusen mit WT- und hslV-KO-Parasiten nicht signifikant nachweisbar. 
Das Phänomen ließe sich durch eine Interaktion von plasmodialem hslV mit 
Toll-like Rezeptoren des Wirtsorganismus, die zu verbesserten 
Wachstumsbedingungen für den Parasiten führt, erklären. Diese verbesserten 
Wachstumsbedingungen fehlen in hslV-defizienten Parasiten oder einem 
MyD88-defizienten Wirtsorganismus, was die reduzierten Vermehrungsraten 
unter diesen Bedingungen erklären würde. Welche Signalübertragungswege 
eine solche Parasit-Wirt-Interaktion vermitteln könnten, ist Gegenstand 
nachfolgender Studien. 
Zusammengenommen weisen die Ergebnisse dieser Arbeit darauf hin, dass 
ClpQ an der Interaktion des Malariaparasiten mit dem angeborenen 
Immunsystem des Wirtsorganismus beteiligt ist und dass es sich somit bei 
hslV um einen möglichen plasmodialen Virulenzfaktor handelt. 
Die Tatsache, dass ClpQ im Wirtsorganismus nicht vorkommt, macht die 
Protease zu einem vielversprechenden Zielmolekül für zukünftige 
Malariatherapeutika bzw. zu einem Impfantigenkandidaten. Im Hinblick auf 
zukünftige Ansätze zur Malariabehandlung oder –prophylaxe, sollte durch 
weitere Experimente geklärt werden, welche Signaltransduktionswege in 
diesem Zusammenhang von Bedeutung sind. 
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